Elanco delivered a strong first quarter, exceeding guidance in key areas and driving growth through innovation and strategic initiatives. Despite challenges in U.S. retail and tariffs, the company demonstrated resilience and proactive management, resulting in a positive outlook for the rest of the year.

Company Guidance -

Q1 2025

During Elanco Animal Health's Q1 2025 earnings call, the company provided guidance that exceeded its initial forecasts, specifically for revenue, adjusted EBITDA, and adjusted EPS. The company reported a 4% organic constant currency revenue growth, driven equally by price and volume. Elanco raised its full-year expectations for revenue from new products to $660 million to $740 million, highlighting innovations like Credelio Quattro and Zenrelia. The company also improved its net leverage target to 3.9x to 4.3x by year-end due to strong working capital performance and favorable currency shifts. Elanco expects 2025 full-year organic constant currency revenue growth of 4% to 6%, maintaining a full-year adjusted EBITDA range of $830 million to $870 million and adjusted EPS between $0.80 and $0.86. Despite external uncertainties including tariffs, Elanco remains confident in its strategy, emphasizing growth, innovation, and cash flow to enhance its long-term value proposition.

Exceeded First Quarter Guidance

Elanco exceeded first quarter guidance for revenue, adjusted EBITDA, and adjusted EPS with 4% organic constant currency revenue growth, driven by both price and volume.

Strong Innovation Revenue

$198 million in first-quarter revenue from new products, leading to an increased full-year expectation of $660 million to $740 million.

Deleveraging Progress

Improved net leverage target for year-end to 3.9x to 4.3x, reflecting strong working capital performance and favorable currency impacts.

Positive Trends in Farm Animal Business

U.S. Farm Animal business grew 17%, with Experior leading growth due to rapid adoption and new FDA clearance.

Elanco Animal Health (ELAN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ELAN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 11, 2025	2025 (Q2)	0.20 / -	0.3	―	―	―
May 07, 2025	2025 (Q1)	0.31 / 0.37	0.34	8.82% (+0.03)
Feb 25, 2025	2024 (Q4)	0.15 / 0.14	0.08	75.00% (+0.06)
Nov 07, 2024	2024 (Q3)	0.12 / 0.13	0.18	-27.78% (-0.05)
Aug 08, 2024	2024 (Q2)	0.24 / 0.30	0.18	66.67% (+0.12)
May 08, 2024	2024 (Q1)	0.27 / 0.34	0.45	-24.44% (-0.11)
Feb 26, 2024	2023 (Q4)	0.10 / 0.08	0.19	-57.89% (-0.11)
Nov 07, 2023	2023 (Q3)	0.13 / 0.18	0.2	-10.00% (-0.02)
Aug 07, 2023	2023 (Q2)	0.05 / 0.18	0.36	-50.00% (-0.18)
May 09, 2023	2023 (Q1)	0.28 / 0.45	0.36	25.00% (+0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ELAN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$9.51	$12.01	+26.29%
Feb 25, 2025	$11.11	$10.70	-3.69%
Nov 07, 2024	$12.86	$14.50	+12.75%
Aug 08, 2024	$12.38	$12.99	+4.93%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.